Associated Papers
Empagliflozin restores neutropenia and neutrophil dysfunction in a young patient with severe congenital neutropenia type 4.
Lédeczi Z et al.
The Journal of Allergy and Clinical Immunology. in Practice, 2023
Severe congenital neutropenia due to G6PC3 deficiency: Case series of five patients and literature review.
Velez-Tirado N et al.
Scandinavian Journal of Immunology, 2022
Severe Congenital Neutropenia Type 4: A Rare Disease Harboring a G6pc3 Gene Pathogenic Variant Particular to the Mexican Population.
López-Rodríguez L et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2022
Lentiviral gene therapy and vitamin B3 treatment enable granulocytic differentiation of G6PC3-deficient induced pluripotent stem cells.
Hoffmann D et al.
Gene Therapy, 2020
A Severe Congenital Neutropenia Type 4 Case (G6PC3 Mutation) Presented With Large Platelets in the Peripheral Smear.
Kaymak Cihan M et al.
Journal of Pediatric Hematology/oncology, 2016
A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations.
Banka S et al.
Orphanet Journal of Rare Diseases, 2013
A syndrome with congenital neutropenia and mutations in G6PC3.
Boztug K et al.
The New England Journal of Medicine, 2009
Select a paper to view details